Combination of Infliximab and High-Dose Intravenous Immunoglobulin for Toxic Epidermal Necrolysis: Successful Treatment of an Elderly Patient
Figure 1
Detail of patient’s face. Panel (a): diffuse erythema and beginning of detachment of the epidermis at admission. Panel (b): at day 4 of hospitalization presence of hemorrhagic stomatitis and cheilitis, however with already arrested disease progression in the skin. Panel (c): state of complete recovery at 9-month follow-up appointment.
